Literature DB >> 26399239

Why are kids with lupus at an increased risk of cardiovascular disease?

Catherine Quinlan1, Stephen D Marks2, Kjell Tullus2.   

Abstract

Juvenile-onset systemic lupus erythematosus (SLE) is an aggressive multisystem autoimmune disease. Despite improvements in outcomes for adult patients, children with SLE continue to have a lower life expectancy than adults with SLE, with more aggressive disease, a higher incidence of lupus nephritis and there is an emerging awareness of their increased risk of cardiovascular disease (CVD). In this review, we discuss the evidence for an increased risk of CVD in SLE, its pathogenesis, and the clinical approach to its management.

Entities:  

Keywords:  Adipokines; Cardiovascular; Lipids; Physical activity; Systemic lupus erythematosus

Mesh：

Substances：

Year:  2015        PMID： 26399239     DOI： 10.1007/s00467-015-3202-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  258 in total

1.  Risk factors related to hypertension in a Spanish systemic lupus erythematosus cohort.

Authors:  J M Sabio; J D Mediavilla; C Fernández-Torres; L Aliaga; J Jiménez-Alonso
Journal:  Lupus       Date:  2001       Impact factor: 2.911

2.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.

Authors:  M B Urowitz; D Gladman; D Ibañez; S C Bae; J Sanchez-Guerrero; C Gordon; A Clarke; S Bernatsky; P R Fortin; J G Hanly; D J Wallace; D Isenberg; A Rahman; G S Alarcón; J T Merrill; E Ginzler; M Khamashta; O Nived; G Sturfelt; I N Bruce; K Steinsson; S Manzi; R Ramsey-Goldman; M A Dooley; A Zoma; K Kalunian; M Ramos; R F Van Vollenhoven; C Aranow; T Stoll; M Petri; P Maddison
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

3.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

4.  The cardiovascular threat of lupus.

Authors:  Joan M Von Feldt
Journal:  Nat Clin Pract Rheumatol       Date:  2008-10

5.  Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Authors:  L E Schanberg; C Sandborg; H X Barnhart; S P Ardoin; E Yow; G W Evans; K L Mieszkalski; N T Ilowite; A Eberhard; L F Imundo; Y Kimura; E von Scheven; E Silverman; S L Bowyer; M Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L Jung; J B Soep; A M Reed; J Provenzale; S D Thompson
Journal:  Arthritis Rheum       Date:  2012-01

6.  Adiponectin induces dendritic cell activation via PLCγ/JNK/NF-κB pathways, leading to Th1 and Th17 polarization.

Authors:  Mi Young Jung; Han-Soo Kim; Hye-Jin Hong; Byung-Soo Youn; Tae Sung Kim
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

Review 7.  The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?

Authors:  C B Narshi; I P Giles; A Rahman
Journal:  Lupus       Date:  2010-12-07       Impact factor: 2.911

8.  Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease.

Authors:  A R Kranenburg; W I de Boer; V K T Alagappan; P J Sterk; H S Sharma
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

9.  Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin.

Authors:  Ling Li; Jean-Claude Mamputu; Nicolas Wiernsperger; Geneviève Renier
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

10.  Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin.

Authors:  Fred Haugen; Christian A Drevon
Journal:  Endocrinology       Date:  2007-08-16       Impact factor: 4.736
View more
  6 in total

1.  Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.

Authors:  Julien Hogan; Astrid Godron; Véronique Baudouin; Theresa Kwon; Jérôme Harambat; Georges Deschênes; Olivier Niel
Journal:  Pediatr Nephrol       Date:  2017-08-05       Impact factor: 3.714

Review 2.  Management and outcomes in children with lupus nephritis in the developing countries.

Authors:  Priyanka Khandelwal; Srinivasavaradan Govindarajan; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2022-10-18       Impact factor: 3.651

3.  Differential gene expression profiles in peripheral blood in Northeast Chinese Han people with acute myocardial infarction.

Authors:  Lin Fan; Heyu Meng; Xudong Guo; Xiangdong Li; Fanbo Meng
Journal:  Genet Mol Biol       Date:  2018 Jan-Mar       Impact factor: 1.771

4.  Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study.

Authors:  Meredith A Atkinson; Sarah Joo; Sangeeta Sule
Journal:  PLoS One       Date:  2019-03-29       Impact factor: 3.240

5.  Juvenile systemic lupus erythematosus presenting as pancarditis.

Authors:  D O'Leary; C O'Connor; L Nertney; E J MacDermott; D Mullane; O Franklin; O G Killeen
Journal:  Pediatr Rheumatol Online J       Date:  2019-11-04       Impact factor: 3.054

Review 6.  The potential role of Colchicine in preventing coronary vascular disease in childhood-onset lupus: a new view on an old drug.

Authors:  Dori Abel; Stacy P Ardoin; Mark Gorelik
Journal:  Pediatr Rheumatol Online J       Date:  2021-02-16       Impact factor: 3.054
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.